secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001193125-23-292706
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio raises $14.4M in private placement; potential total up to $46.9M via warrant exercises
--------------------------------------------------------------------------------

- Initial gross proceeds of $14.4M from selling 11.8M units at $1.22/unit; extends cash runway into 2025.
- Investors get Series A warrants ($1.25 strike) exercisable upon INB-100 11-month data announcement for up to $14.8M additional.
- Series B warrants ($1.50 strike) redeemable upon 22-month data; potential $17.7M extra if all exercised.
- Pre-funded warrants at $0.0001 exercise price included; Cantor Fitzgerald acted as sole placement agent.
- Proceeds to fund clinical development of gamma-delta T cell therapies and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/0001193125-23-292706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/d634758d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-292706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer